Memantine Effects on Sensorimotor Gating and Neurocognition in Schizophrenia
Status: | Recruiting |
---|---|
Conditions: | Healthy Studies, Schizophrenia, Psychiatric, Psychiatric |
Therapuetic Areas: | Psychiatry / Psychology, Other |
Healthy: | No |
Age Range: | 18 - 50 |
Updated: | 3/6/2019 |
Start Date: | April 1, 2018 |
End Date: | March 2021 |
Contact: | Jo Talledo Benrubi, B.A. |
Email: | atalledo@ucsd.edu |
Phone: | 6195433093 |
This application seeks to determine if neurophysiological metrics of memantine (MEM)-enhanced
early auditory information processing (EAIP) in schizophrenia (SZ) mediate gains in auditory
processing fidelity (APF) and auditory learning.
early auditory information processing (EAIP) in schizophrenia (SZ) mediate gains in auditory
processing fidelity (APF) and auditory learning.
Inclusion Criteria:
- diagnosis of schizophrenia OR schizoaffective-depressed OR healthy subjects
- ages 18-50 for all subjects
- double barrier contraception for all subjects
- not pregnant for all subjects
Exclusion Criteria:
- DSM-IV Axis I or II Diagnosis for for healthy subjects
- MEM or amantadine for patients
- current substance abuse for all subjects
- current recreational drug use for all subjects
- history of other significant medical illness (e.g. cancer, diabetes, heart disease,
HIV, seizures) for all subjects
- open head injury or closed head injury with loss of consciousness > 1 min for all
subjects
- hearing or visual impairment for all subjects
- pregnancy for all subjects
- dementia for all subjects
- mental retardation for all subjects
We found this trial at
1
site
San Diego, California 92103
Principal Investigator: Neal R. Swerdlow, M.D., Ph.D.
Phone: 619-543-3093
Click here to add this to my saved trials